New pill could stop scarring hair loss in its tracks
NCT ID NCT07508488
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests a daily pill called deucravacitinib in 20 adults with two types of scarring hair loss (CCCA and FFA). The goal is to see if it can reduce inflammation and scarring on the scalp over 48 weeks. All participants receive the drug, and researchers will measure changes in immune markers and hair loss severity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRONTAL FIBROSING ALOPECIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Deucravacitinib (a pill that targets inflammation)
What this could lead to
If it works, this could point toward a new treatment option for people with scarring hair loss, potentially slowing or stopping hair loss.
What could go wrong
This is a small, early-phase trial with only 20 participants and no placebo group. It mainly looks at biological markers, not hair regrowth, so results may not lead to a proven treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.